Next Article in Journal
Novel Drug Delivery Method Targeting Para-Aortic Lymph Nodes by Retrograde Infusion of Paclitaxel into Pigs’ Thoracic Duct
Next Article in Special Issue
The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk?
Previous Article in Journal
Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Pathology of Urologic Cancers

by
Giovanni Tossetta
1,* and
Roberta Mazzucchelli
2,*
1
Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy
2
Department of Biomedical Sciences and Public Health, Section of Pathological Anatomy, Università Politecnica delle Marche, 60126 Ancona, Italy
*
Authors to whom correspondence should be addressed.
Cancers 2022, 14(15), 3751; https://doi.org/10.3390/cancers14153751
Submission received: 15 July 2022 / Accepted: 29 July 2022 / Published: 1 August 2022
(This article belongs to the Special Issue Pathology of Urogenital Cancers)
We are pleased to present this Special Issue of Cancers, entitled “Pathology of Urologic Cancers”. Urologic cancers include kidney, bladder and prostate cancer, and are in the top-ten list of human cancers. The incidence of urologic malignancies has increased significantly over the last 50 years [1]. Despite advances in medical tumor therapy, the occurrence of chemoresistance and metastatic disease is a common cause of death in patients with urological malignancies [2,3,4]. The pathogenetic mechanisms of kidney, bladder and prostate tumors are very different and represent an important challenge for clinical teams, requiring close collaboration among urologists, oncologists and pathologists [5,6,7,8]. Moreover, the expression level of specific proteins that are detectable by immunohistochemistry and the use of molecular biomarkers are reported to be helpful in predicting the recurrence, progression and development of metastasis. For these reasons, novel biomarkers are always needed in clinical practice for patient risk stratification and personalized therapy to develop new therapeutic approaches that can improve diagnosis and treatment outcomes [9,10]. To this end, we require a better understanding of the molecular changes that occur in urological tumors and the development of molecular biomarkers that are able to predict tumor behavior and the risk of disease recurrence and chemoresistance.
In recent decades, intense research efforts have focused on identifying novel biomarkers (DNA, microRNAs, lncRNAs, proteins, etc.), which could be used for diagnosis [11,12,13,14], prognosis [15,16,17,18], or as a therapeutical target [19,20,21,22], with an important impact on neoplastic diseases [23,24].
Thus, finding useful biomarkers that can allow for the early and appropriate treatment of urologic malignancies represents a key point to improve the outcome of these diseases.
The usefulness of specific biomarkers could help to increase understanding of the complexity of some urologic tumors with very heterogeneous malignancy [25,26]. In renal cancer, particularly clear cell renal cell carcinomas (CCRCC), VHL mutation or methylation and chromosomal gains and losses are considered tumor initiators and have lethal potential for the neoplasms [27]. Moreover, it has been reported that exosomes, small membrane vesicles secreted by cells into the extracellular space, are involved in tumorigenesis and can be used to distinguish muscle-invasive bladder cancer from its non-invasive counterparts [28]. Furthermore, patients harboring germline mutations in specific genes (e.g., BRCA1/2) showed an increased chance of developing aggressive prostate cancer with a high mortality rate [29].
In addition, the metabolism of neoplastic cells and the microenvironment play an important role in the development and progression of cancer.
Cancer has been often associated with chronic inflammation and oxidative stress [30,31,32]. Oxidative stress plays a key role cancer development, including urologic cancers [33]. The production of reactive oxygen and nitrogen species (ROS/RNS) is normally associated with physiological processes such as oxidative respiration. When the rate of ROS/RNS generation is balanced by the scavenging activity of antioxidant compounds, e.g., glutathione (GSH), the redox homeostatic balance is maintained. In the case of elevated ROS levels, the latter cannot be counteracted by the cellular antioxidant response, causing a redox imbalance that results in oxidative injures to cell organelles [34], leading to the development of several diseases, including cancer [30].
Natural products (often called phytonutrients) are biological compounds present in plants (e.g., carotenoids, anthocyanins and flavonoids) as well as in bacteria, fungi and marine organisms. Many of these compounds are used as cancer adjuvants, since they can attenuate chemotherapeutic resistance and also counteract some side effects of these chemotherapeutic agents. Moreover, several natural compounds have recently been proposed as immunity regulators in various cancer types since they can regulate the activity of many immune cell types, including T and B lymphocytes, natural killer (NK), Treg and dendritic cells. In this way, these compounds can regulate cytokine production in the tumor microenvironment, regulating cancer cell growth and proliferation [35].
Understanding the mechanisms involved in the regulation of urological cancer development/progression and the main modulators involved in the activation/inhibition of the pivotal signaling pathways in these malignancies can lead to new perspectives in the treatment of these pathologies. Thus, the aim of this Special Issue is to provide an overview of the molecular and signaling alterations involved in urological cancer’s development, diagnosis and treatment.

Author Contributions

Conceptualization, R.M.; writing—original draft preparation, G.T. and R.M.; writing—review and editing, G.T. and R.M.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Campagna, R.; Pozzi, V.; Spinelli, G.; Sartini, D.; Milanese, G.; Galosi, A.B.; Emanuelli, M. The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update. Biomolecules 2021, 11, 1214. [Google Scholar] [CrossRef]
  2. Paramanantham, Y.; Chung, I.; Said, N.A.B. The role of tumour microenvironment-driven miRNAs in the chemoresistance of muscle-invasive bladder cancer-a review. Urol. Oncol. 2022, 40, 133–148. [Google Scholar] [CrossRef]
  3. Mickisch, G.H. Chemoresistance of renal cell carcinoma: 1986–1994. World J. Urol. 1994, 12, 214–223. [Google Scholar] [CrossRef] [Green Version]
  4. Culig, Z. miRNA as Regulators of Prostate Carcinogenesis and Endocrine and Chemoresistance. Curr. Cancer Drug Targets 2021, 21, 283–288. [Google Scholar] [CrossRef]
  5. Mazzucchelli, R.; Marzioni, D.; Tossetta, G.; Pepi, L.; Montironi, R. Bladder Cancer Sample Handling and Reporting: Pathologist’s Point of View. Front. Surg. 2021, 8, 754741. [Google Scholar] [CrossRef]
  6. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef]
  7. Marzioni, D.; Lorenzi, T.; Mazzucchelli, R.; Capparuccia, L.; Morroni, M.; Fiorini, R.; Bracalenti, C.; Catalano, A.; David, G.; Castellucci, M.; et al. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int. J. Immunopathol. Pharmacol. 2009, 22, 627–638. [Google Scholar] [CrossRef]
  8. Tossetta, G.; Fantone, S.; Gesuita, R.; Montironi, R.; Marzioni, D.; Mazzucchelli, R. AT-rich interactive domain 1A (ARID1A) cannot be considered a morphological marker for prostate cancer progression: A pilot study. Acta Histochem. 2022, 124, 151847. [Google Scholar] [CrossRef]
  9. Cimadamore, A.; Gasparrini, S.; Santoni, M.; Cheng, L.; Lopez-Beltran, A.; Battelli, N.; Massari, F.; Giunchi, F.; Fiorentino, M.; Scarpelli, M.; et al. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev. Mol. Diagn. 2018, 18, 645–655. [Google Scholar] [CrossRef]
  10. Montironi, R.; Cheng, L.; Cimadamore, A.; Lopez-Beltran, A. Molecular diagnostics in uro-oncology. Expert Rev. Mol. Diagn. 2020, 20, 117–121. [Google Scholar] [CrossRef] [Green Version]
  11. Pozzi, V.; Di Ruscio, G.; Sartini, D.; Campagna, R.; Seta, R.; Fulvi, P.; Vici, A.; Milanese, G.; Brandoni, G.; Galosi, A.B.; et al. Clinical performance and utility of a NNMT-based urine test for bladder cancer. Int. J. Biol. Markers 2018, 33, 94–101. [Google Scholar] [CrossRef] [PubMed]
  12. Ganzetti, G.; Sartini, D.; Campanati, A.; Rubini, C.; Molinelli, E.; Brisigotti, V.; Cecati, M.; Pozzi, V.; Campagna, R.; Offidani, A.; et al. Nicotinamide N-methyltransferase: Potential involvement in cutaneous malignant melanoma. Melanoma Res. 2018, 28, 82–88. [Google Scholar] [CrossRef] [PubMed]
  13. Campagna, R.; Pozzi, V.; Sartini, D.; Salvolini, E.; Brisigotti, V.; Molinelli, E.; Campanati, A.; Offidani, A.; Emanuelli, M. Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. Cancers 2021, 13, 4943. [Google Scholar] [CrossRef] [PubMed]
  14. Fujita, K.; Nonomura, N. Urinary biomarkers of prostate cancer. Int. J. Urol. 2018, 25, 770–779. [Google Scholar] [CrossRef] [Green Version]
  15. Bacchetti, T.; Salvolini, E.; Pompei, V.; Campagna, R.; Molinelli, E.; Brisigotti, V.; Togni, L.; Lucarini, G.; Sartini, D.; Campanati, A.; et al. Paraoxonase-2, A potential biomarker for skin cancer aggressiveness. Eur. J. Clin. Investig. 2021, 51, e13452. [Google Scholar] [CrossRef]
  16. Sartini, D.; Campagna, R.; Lucarini, G.; Pompei, V.; Salvolini, E.; Mattioli-Belmonte, M.; Molinelli, E.; Brisigotti, V.; Campanati, A.; Bacchetti, T.; et al. Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. Hum. Cell 2021, 34, 1929–1931. [Google Scholar] [CrossRef]
  17. Liu, Z.; Zhong, J.; Cai, C.; Lu, J.; Wu, W.; Zeng, G. Immune-related biomarker risk score predicts prognosis in prostate cancer. Aging 2020, 12, 22776–22793. [Google Scholar] [CrossRef]
  18. Zhang, D.; Du, D.; Yi, S.; Li, X. LncRNA PCAT6, A potential biomarker for diagnosis and prognosis of bladder cancer. Ann. Diagn. Pathol. 2020, 49, 151642. [Google Scholar] [CrossRef]
  19. Campagna, R.; Bacchetti, T.; Salvolini, E.; Pozzi, V.; Molinelli, E.; Brisigotti, V.; Sartini, D.; Campanati, A.; Ferretti, G.; Offidani, A.; et al. Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin. Antioxidants 2020, 9, 1238. [Google Scholar] [CrossRef]
  20. Campagna, R.; Salvolini, E.; Pompei, V.; Pozzi, V.; Salvucci, A.; Molinelli, E.; Brisigotti, V.; Sartini, D.; Campanati, A.; Offidani, A.; et al. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment. Cell Melanoma Res. 2021, 34, 1039–1048. [Google Scholar] [CrossRef]
  21. Su, Y.; Feng, W.; Shi, J.; Chen, L.; Huang, J.; Lin, T. circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-beta2/smad3 pathway. Mol. Cancer 2020, 19, 23. [Google Scholar] [CrossRef] [Green Version]
  22. Kancherla, P.; Daneshvar, M.; Sager, R.A.; Mollapour, M.; Bratslavsky, G. Fumarate hydratase as a therapeutic target in renal cancer. Expert Opin. Ther. Targets 2020, 24, 923–936. [Google Scholar] [CrossRef]
  23. Tossetta, G.; Fantone, S.; Montanari, E.; Marzioni, D.; Goteri, G. Role of NRF2 in Ovarian Cancer. Antioxidants 2022, 11, 663. [Google Scholar] [CrossRef]
  24. Avellini, C.; Licini, C.; Lazzarini, R.; Gesuita, R.; Guerra, E.; Tossetta, G.; Castellucci, C.; Giannubilo, S.R.; Procopio, A.; Alberti, S.; et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget 2017, 8, 58642–58653. [Google Scholar] [CrossRef] [Green Version]
  25. Campagna, R.; Cecati, M.; Pozzi, V.; Fumarola, S.; Pompei, V.; Milanese, G.; Galosi, A.B.; Sartini, D.; Emanuelli, M. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Mol. Biol. 2018, 64, 51–55. [Google Scholar] [CrossRef]
  26. Manini, C.; Lopez, J.I. The Labyrinth of Renal Cell Carcinoma. Cancers 2020, 12, 521. [Google Scholar] [CrossRef] [Green Version]
  27. Jonasch, E.; Walker, C.L.; Rathmell, W.K. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat. Rev. Nephrol. 2021, 17, 245–261. [Google Scholar] [CrossRef]
  28. Baumgart, S.; Holters, S.; Ohlmann, C.H.; Bohle, R.; Stockle, M.; Ostenfeld, M.S.; Dyrskjot, L.; Junker, K.; Heinzelmann, J. Exosomes of invasive urothelial carcinoma cells are characterized by a specific miRNA expression signature. Oncotarget 2017, 8, 58278–58291. [Google Scholar] [CrossRef] [Green Version]
  29. Na, R.; Zheng, S.L.; Han, M.; Yu, H.; Jiang, D.; Shah, S.; Ewing, C.M.; Zhang, L.; Novakovic, K.; Petkewicz, J.; et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur. Urol. 2017, 71, 740–747. [Google Scholar] [CrossRef] [Green Version]
  30. Barrera, G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012, 2012, 137289. [Google Scholar] [CrossRef] [Green Version]
  31. Papadakos, S.P.; Dedes, N.; Kouroumalis, E.; Theocharis, S. The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity. Cancers 2022, 14, 3150. [Google Scholar] [CrossRef]
  32. Emanuelli, M.; Sartini, D.; Molinelli, E.; Campagna, R.; Pozzi, V.; Salvolini, E.; Simonetti, O.; Campanati, A.; Offidani, A. The Double-Edged Sword of Oxidative Stress in Skin Damage and Melanoma: From Physiopathology to Therapeutical Approaches. Antioxidants 2022, 11, 612. [Google Scholar] [CrossRef]
  33. Fumarola, S.; Cecati, M.; Sartini, D.; Ferretti, G.; Milanese, G.; Galosi, A.B.; Pozzi, V.; Campagna, R.; Morresi, C.; Emanuelli, M.; et al. Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression. Antioxidants 2020, 9, 175. [Google Scholar] [CrossRef] [Green Version]
  34. Taucher, E.; Mykoliuk, I.; Fediuk, M.; Smolle-Juettner, F.M. Autophagy, Oxidative Stress and Cancer Development. Cancers 2022, 14, 1637. [Google Scholar] [CrossRef]
  35. Gupta, M.; Chandan, K.; Sarwat, M. Natural Products and their Derivatives as Immune Check Point Inhibitors: Targeting Cytokine/Chemokine Signalling in Cancer. Semin. Cancer Biol. 2022; in press. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Tossetta, G.; Mazzucchelli, R. Pathology of Urologic Cancers. Cancers 2022, 14, 3751. https://doi.org/10.3390/cancers14153751

AMA Style

Tossetta G, Mazzucchelli R. Pathology of Urologic Cancers. Cancers. 2022; 14(15):3751. https://doi.org/10.3390/cancers14153751

Chicago/Turabian Style

Tossetta, Giovanni, and Roberta Mazzucchelli. 2022. "Pathology of Urologic Cancers" Cancers 14, no. 15: 3751. https://doi.org/10.3390/cancers14153751

APA Style

Tossetta, G., & Mazzucchelli, R. (2022). Pathology of Urologic Cancers. Cancers, 14(15), 3751. https://doi.org/10.3390/cancers14153751

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop